PDF(Pubmed)
Abstract：
The gut microbiota is now considered as a key player in the development of metabolic dysfunction. Therefore, targeting gut microbiota dysbiosis has emerged as a new therapeutic strategy, notably through the use of live gut microbiota-derived biotherapeutics. We previously highlighted the anti-inflammatory abilities of two Parabacteroides distasonis strains. We herein evaluate their potential anti-obesity abilities and show that the two strains induced the secretion of the incretin glucagon-like peptide 1 in vitro and limited weight gain and adiposity in obese mice. These beneficial effects are associated with reduced inflammation in adipose tissue and the improvement of lipid and bile acid metabolism markers. P. distasonis supplementation also modified the Actinomycetota, Bacillota and Bacteroidota taxa of the mice gut microbiota. These results provide better insight into the capacity of P. distasonis to positively influence host metabolism and to be used as novel source of live biotherapeutics in the treatment and prevention of metabolic-related diseases.
摘要：
肠道微生物群现在被认为是代谢功能障碍发展的关键参与者。因此,靶向肠道微生物群失调已经成为一种新的治疗策略，特别是通过使用活的肠道微生物群衍生的生物治疗剂。我们先前强调了两种双反杆菌属菌株的抗炎能力。我们在此评估了它们的潜在抗肥胖能力，并表明这两种菌株在体外诱导肠促胰岛素胰高血糖素样肽1的分泌，并限制了肥胖小鼠的体重增加和肥胖。这些有益作用与脂肪组织中炎症的减少以及脂质和胆汁酸代谢标志物的改善有关。食道杆菌的补充也改变了放线菌，小鼠肠道微生物群的芽孢杆菌和拟杆菌分类群。这些结果提供了更好地了解地皮杆菌积极影响宿主代谢的能力，并将其用作治疗和预防代谢相关疾病的活生物治疗剂的新来源。
